Disease Info Card

Mastocytosis, Systemic

Information about Mastocytosis, Systemic: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Mastocytosis, Systemic

Most recent studies have shown that Mastocytosis, Systemic shares some biological mechanisms with aggressive-systemic-mastocytosis, anaphylaxis, cutaneous-mastocytosis, diarrhea, eosinophilia, flushing, hematological-disease, leukemia, leukemia-mast-cell, leukemia-myelocytic-acute, malignant-neoplasms, malignant-paraganglionic-neoplasm, mastocytosis, myeloid-leukemia, myeloproliferative-disease, neoplasms, osteoporosis, pain, urticaria, urticaria-pigmentosa.

Among the many pathways, these few ones have gauged particular interests from scientists studying Mastocytosis, Systemic, and have been seen in publications frequently: Acid Secretion, Anaphylaxis, Angiogenesis, Bone Remodeling, Bone Resorption, Cell Activation, Cell Cycle, Cell Development, Cell Differentiation, Cell Growth, Cell Proliferation, Coagulation, Excretion, Localization, Mast Cell Activation, Mast Cell Degranulation, Mast Cell Differentiation, Mast Cell Proliferation, Pathogenesis, Secretion

Quite a number of genes have been found to play important roles in Mastocytosis, Systemic, such as ASXL1, BCR, CD2, CD34, CTLA4, DIO2, HLA-DQA1, IL2RA, ISG20, JAK2, KIT, KITLG, NOD2, PDGFRA, PDGFRB, TPSD1, TPSG1. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.